<DOC>
	<DOCNO>NCT02309177</DOCNO>
	<brief_summary>The purpose study assess safety nab-paclitaxel base chemotherapy regimen administer prior and/or combination nivolumab Pancreatic Cancer , Non Small Cell Lung Cancer ( NSCLC ) Metastatic Breast Cancer ( mBC ) .</brief_summary>
	<brief_title>Safety Study Nivolumab With Nab-Paclitaxel Plus Minus Gemcitabine Pancreatic Cancer , Nab-Paclitaxel / Carboplatin Stage IIIB/IV Non-Small Cell Lung Cancer Nab-Paclitaxel Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>This phase 1 , open-label , multicenter , safety study nab-paclitaxel base chemotherapy regimen administer prior and/or combination nivolumab Pancreatic Cancer , NSCLC mBC . This six arm study assess two treatment arm per tumor-type/indication : - Adenocarcinoma pancreas 1 prior systemic chemotherapy ( Arm A , Part 1 ) ; subsequently prior chemotherapy , surgery radiation therapy locally advance metastatic disease ( Arm A , Part 2 Arm B ) : - Panc Ca Arm A : nab-paclitaxel nivolumab start Cycle 1 . - Panc Ca Arm B : nab-paclitaxel/gemcitabine nivolumab start Cycle 1 . - Stage IIIB IV NSCLC prior chemotherapy metastatic disease candidate curative surgery radiation : - NSCLC Arm C : nab-paclitaxel/carboplatin x 4 cycle nivolumab start Cycle 1 continue monotherapy start Cycle 5 . - NSCLC Arm D : nab-paclitaxel/carboplatin x 4 cycle nivolumab start Cycle 3 continue monotherapy start Cycle 5 - HER2-negative recurrent metastatic breast cancer one prior regimen mBC , include anthracycline unless clinically contraindicate : - mBC Arm E : weekly nab-paclitaxel nivolumab start Cycle 3 . - mBC Arm F : q3weekly nab-paclitaxel nivolumab start Cycle 3 . Enrollment treatment arm conduct two sequential part allow evaluation DLT Part 1 prior expand treatment arm Part 2 . Part 1 : Part 1 ass Dose Limiting Toxicity ( DLT ) nivolumab dose combination nab-paclitaxel regimen treatment arm . Subjects meet entry criterion assign respective treatment arm base tumor type indication outline . Panc Ca Arms A B , well NSCLC Arms C D , enroll sequentially Part 1 . The safety nivolumab combination nabpaclitaxel , without gemcitabine , first assess Arm A subject one prior systemic chemotherapy regimen locally advance metastatic disease . Panc Ca Arm B may begin enrol subject Part 1 , Panc Ca Arm A deem safe , base DLT criterion . Similarly , NSCLC Arm D begin enroll Part 1 NSCLC Arm C deem safe expand Part 2 . However , Arm D may initiate , even Arm C proceed Part 2 , totality data Arm C emerge data study NSCLC nivolumab combination platinum chemotherapy doublet support decision . Unlike Panc Ca NSCLC arm , two mBC arm ( Arms E F ) initiate simultaneously . Subjects assign randomly treatment arm tumor type/indication whenever treatment arm enrol . An IRT system use ensure central random allocation subject . Part 2 : Treatment arm deem safe within tumor-type/indication may expand use RP2D additional approximately 14 subject ( attain total 20 nivolumab-treated subject ) assess safety tolerability , well explore anti-tumor activity propose regimen . Since primary population pancreas arm subject prior chemotherapy , surgery radiation therapy , enrollment Part 2 Panc Ca Arm A continue 20 subject treat least one dose nivolumab . Additionally , Parts 1 2 overall , mBC Arm ( E F ) enroll minimum 9 subject triple- negative breast cancer ( TNBC ) , treat RP2D . For Part 1 2 , subject may continue receive assign treatment regimen Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 define progression unacceptable toxicity . However , chemotherapy doublet give 4 cycle NSCLC arm ; thereafter , nivolumab give monotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subject male female , ≥ 18 year old time signing informed consent form ( ICF ) . 2 . Subject confirm diagnosis advance unresectable solid tumor target subject population within parameter mention : 1 . Pancreatic Cancer Subject definitive histologically cytologically confirm locally advanced metastatic adenocarcinoma pancreas . Subjects islet cell neoplasms exclude . nabPaclitaxel Nivolumab : Subjects must receive 1 prior systemic chemotherapy regimen locally advance metastatic disease . nabPaclitaxel + Nivolumab nabpaclitaxel , Gemcitabine Nivolumab : Subjects must receive previous radiotherapy , surgery , chemotherapy investigational therapy treatment locally advance metastatic disease . Subjects receive cytotoxic dos gemcitabine chemotherapy adjuvant set eligible inclusion . Prior treatment 5FU gemcitabine administer radiation sensitizer adjuvant setting allow , ≥ 6 month must elapse since completion last dose linger toxicity may present . Initial diagnosis metastatic disease must occur ≤6 week prior randomization study . 2 . Nonsmall Cell Lung Cancer ( NSCLC ) : Subject definitive histologically cytologically confirm Stage IIIB IV NSCLC . Subjects must receive previous chemotherapy investigational therapy treatment metastatic disease . Adjuvant chemotherapy permit provide cytotoxic chemotherapy complete &gt; 12 month prior randomization , without disease recurrence progression 12 month . 3 . Metastatic Breast Cancer : Human Epidermal Growth Factor Receptor 2 negative ( HER2 ( ) ) recurrent Metastatic Breast Cancer : Subject definitive histologically cytologically confirm diagnosis HER2 ( ) metastatic breast cancer . Subject receive zero one prior cytotoxic chemotherapy regimen metastatic disease , regardless prior target therapy ( eg . everolimus , palbociclib lapatinib ) , biologic ( eg . trastuzumab ) hormonal therapy treatment ( eg . aromatase inhibitor , selective estrogen receptor modulators , estrogen receptor downregulators ) . If subject receive solventbased paclitaxel ( TAXOL ) docetaxel adjuvant chemotherapy , subject must relapse breast cancer within 12 month complete say therapy . Suitable candidate single agent nabpaclitaxel assess investigator . Subject measurable disease accord RECIST 1.1 . 3 . Archival formalinfixed , paraffinembedded tumor sample collect within 90 day prior subject consent available subject biopsiable metastatic lesion willing undergo biopsy . 4 . Subject malignancy within 5 year , except nonmelanoma skin cancer , cervical intraepithelial neoplasia , insitu cervical cancer . 5 . Subject follow laboratory value screen : WBCs ≥ 2000/uL , Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , Hemoglobin ( Hgb ) ≥ 90 g/L , Platelets ( plt ) ≥ 100 x 109/L , Potassium within normal range , correctable supplement , Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤ 2.5 x Upper Limit Normal ( ULN ) ≤ 3.0 x ULN liver tumor present , Serum total bilirubin ≤ 1.5 x ULN ( except subject Gilbert 's may serum bilirubin &lt; 3.0 x ULN ) , Serum creatinine ≤ 1.5 x ULN , 24hr clearance ≥ 60 mL/min , Normal coagulation [ prothrombin time partial thromboplastin time within normal limit ( ±15 % ) ] . 6 . Subject rest baseline oxygen saturation pulse oximetry ≥ 92 % rest . 7 . Females childbearing potential ( define sexually mature woman : 1 ) undergone hysterectomy ( surgical removal uterus ) bilateral oophorectomy ( surgical removal ovary ) , 2 ) naturally postmenopausal least 24 consecutive month ( ie , menses time precede 24 consecutive month ) must : 1 . Agree write use , able comply , highly effective contraception ( failure rate le 1 % per year ) base Appendix B without interruption study treatment 23 week discontinuation ; 2 . Have negative serum pregnancy test result ( minimum sensitivity 25 IU/L equivalent unit β hCG ( Beta Subunit Human Chorionic Gonadotropin ) ) screen 24 hour prior start IP agree ongoing pregnancy test course study , end study therapy . 3 . Women must breastfeed . ( Females breastfeed receive nivolumab 18 week last dose nivolumab ) . 8 . Male subject agree write use condom sexual contact pregnant female female childbearing potential participating study , dose interruption 31 week follow IP discontinuation , even undergone successful vasectomy . 9 . Subject his/her legally authorize representative guardian understands voluntarily sign inform consent document prior study related assessments/procedures conduct ( except note Section 6 ) . 10 . Subject able adhere study visit schedule protocol requirement . 1 . Subject history allergy hypersensitivity study drug excipients . 2 . Subject symptomatic brain metastasis , spinal cord compression , intractable back pain due compression destructive mass . 3 . Subject active , know suspected autoimmune disease , include systemic lupus erythematodes , Hashimotos thyroiditis , scleroderma , polyarteritis nodosa autoimmune hepatitis . Subjects Type I diabetes mellitus , hypothyroidism require hormone replacement , skin disorder ( vitiligo , psoriasis alopecia ) require systemic treatment , condition expect recur absence external trigger permit enroll . 4 . Subject currently receive require treatment immunosuppressive agent immunosuppressive dos systemic corticosteroid ( unless use treat drugrelated adverse event ) .Topical , ocular , intraarticular , intranasal , inhalational corticosteroid ( minimal systemic absorption ) , use systemic corticosteroid permit per Section 9.1 . 5 . Subject peripheral neuropathy ≥ NCI CTCAE ( National Cancer Institute Common Terminology Criteria Adverse Events ) Grade 2 randomization/enrollment . 6 . Subject history interstitial lung disease , history slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple allergy . Any lung disease may interfere detection management suspect drugrelated pulmonary toxicity . 7 . Subject high cardiovascular risk , include , limited , recent coronary stenting myocardial infarction past year . 8 . Subject unstable angina , significant cardiac arrhythmia , New York Heart Association Class 3 4 congestive heart failure . 9 . Subject history peripheral artery disease ( eg , claudication , Leo Buerger 's disease ) . 10 . Subject major surgery , diagnostic surgery , within 4 week prior treatment study . 11 . Subject know acute chronic pancreatitis . 12 . Subject persistent diarrhea , malabsorption , know subacute bowel obstruction ≥ NCI CTCAE Grade 2 , despite medical management . 13 . Subject active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy . 14 . Subject history test positive Human Immunodeficiency Virus ( HIV ) know acquired immunodeficiency disorder ( AIDS ) . 15 . Subject historical active infection hepatitis B , hepatitis C. 16 . Subject pregnant breastfeeding . 17 . Subject currently enrol clinical protocol investigational trial involve administration experimental therapy and/or therapeutic device , investigational drug . 18 . Subject currently use use within 6 month illicit drug . 19 . Subject significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 20 . Subject condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 21 . Subject condition confounds ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>nab-Paclitaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>mBC</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Triple-negative Breast Cancer</keyword>
	<keyword>Hormone Receptor Positive</keyword>
	<keyword>ER+</keyword>
	<keyword>PR+</keyword>
	<keyword>TNBC</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>PD-1</keyword>
	<keyword>Check-point Inhibitor/s</keyword>
	<keyword>Immune Check-point Inhibitor/s</keyword>
	<keyword>Anti-PD-1</keyword>
	<keyword>BMS-936558</keyword>
</DOC>